NEW YORK (GenomeWeb) – Sequenom and Quest Diagnostics today announced a deal for Quest to offer the MaterniT21 Plus non-invasive prenatal test nationally. Sequenom also announced that the US Food and Drug Administration has issued 510(k) premarket clearance of the firm's Impact Dx system and Impact Dx Factor V Leiden and Factor II Genotyping test.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.

Sep
17
Sponsored by
SeraCare

Today’s challenging clinical next-generation sequencing applications require a rigorous, comprehensive quality control management program to ensure confidence in results.